Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
17th September 2020 | Mark Anthony Mc Camish | 52,398 | Open or private purchase | $5.83 | $305,249.79 |
16th September 2020 | Mark Anthony Mc Camish | 118,602 | Open or private purchase | $5.73 | $679,968.99 |
2nd July 2020 | Jeffrey W Bird | 458,569 | Sale back to the issuer | $18.00 | $8,254,242.00 |
2nd July 2020 | Jeffrey W Bird | 20,475 | Sale back to the issuer | $18.00 | $368,550.00 |
2nd July 2020 | Jeffrey W Bird | 10,007 | Sale back to the issuer | $18.00 | $180,126.00 |
2nd July 2020 | Jeffrey W Bird | 45,402 | Sale back to the issuer | $18.00 | $817,236.00 |
23rd June 2020 | Ann D Rhoads | 4,000 | Open or private purchase | $20.00 | $80,000.00 |
12th June 2020 | Jeffrey W Bird | 7,281 | Grant/award etc. | $0.00 | |
7th April 2020 | Ann D Rhoads | 37,414 | Sale back to the issuer | $0.00 | |
7th April 2020 | Jeffrey W Bird | 215,375 | Sale back to the issuer | $0.00 |
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014.
25th February 2021
12th February 2021
3rd February 2021
8th January 2021
30th December 2020